Navigation Links
Matinas BioPharma to Present at the NYC Medical Technology Forum on February 5, 2013
Date:2/4/2013

TEWKSBURY, N.J. and TARPON SPRINGS, Fla., Feb. 4, 2013 /PRNewswire/ -- Matinas BioPharma, Inc., a biopharmaceutical company focused on the commercialization and development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions, announced today that Roelof Rongen , Matinas BioPharma's Chief Executive Officer, is scheduled to present at the NYC Medical Technology Forum on Tuesday, February 5, 2013 at 6 PM EST.

Mr. Rongen's presentation will include the Company's business outlook for 2013, an overview of the development of its lead product candidate, MAT9001 and its key milestones expected over the next 12 months.  Matinas BioPharma is developing MAT9001 for therapeutic applications, with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL) as the lead indications.  Based on promising early data, the Company is preparing to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and conduct a human study in 2013.  Following positive data from this study, Matinas expects to commence its Phase 3 registration program in the first half of 2014. 

About Matinas BioPharma

Matinas BioPharma Inc. is a privately-held biopharmaceutical company focused on the development of omega-3-based prescription therapeutics for the treatment of metabolic and cardiovascular conditions.  The Company is developing the investigational drug MAT9001 for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) and mixed dyslipidemia (TG 200-499 mg/dL).  Matinas is building on its extensive, proprietary research and development capabilities of its founding management team.  The Matinas BioPharma team brings a cumulative multi-decade omega-3 pharmaceutical development experience to the Company with a proven track record, providing a unique perspective and capability for the development of the next generation of omega-3-fatty-acid-based pharmaceutical products. 

About The NYC Medical Technology Forum (NYC Medtech)

NYC Medtech is a professional platform that assists many different collaborators in the life science, biotech, device and pharma industries have successful outcomes.  This unique program not only brings together companies and investors but all people that are involved from reporters, scientists, academia, trade organizations, international partners et. al. The NYC Medtech program introduces its participants with relevant timely introductions whether through the website, email or the personal touch at the NYC Medtech Forum.  For more information about the NYC Medical Technology Forum visit www.nycmedtech.com.

CONTACT:   
Roelof Rongen
Matinas BioPharma, Inc.
+1-908-443-1870 
info@matinasbiopharma.com


'/>"/>
SOURCE Matinas BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. PDL BioPharma Announces Departure of Finance VP
3. PDL BioPharma Announces 2013 Regular Quarterly Dividends
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. FDAnews announces Biopharmaceutical Good Distribution Practices Summit
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Robust Biopharmaceutical Pipeline Offers New Hope for Patients
8. Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
9. AAIPharma Appoints Senior Director of Biopharmaceutical Development
10. PDL BioPharma Announces Resignation of Chief Financial Officer
11. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... enero de 2017  Hoy, en el Foro Económico ... iniciativa global para avanzar el acceso a la prevención ... de renta baja y baja-media (LICs y LMICs). ... crisis, particularmente en países de renta baja y media, ... las muertes relacionadas con NCD. El objetivo de Access ...
(Date:1/18/2017)... -- With an annual growth ranging from 6% to 10%, South East Asia,s ... Expo, March 22-24, 2017) serves the industry by fostering the regional discourse - ... Investment Forum ASEAN -- India ... content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that Mr. Michael ... the upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, ...
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on ... U.S. Apple Association agrees and recommends starting each day with apples, a habit ... disease. , The U.S. Apple Association – which represents apple growers and producers nationwide ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):